Filing identity and reporting period
The supplied filing is Nukkleus Inc.’s Form 10-K for the fiscal year ended September 30, 2023, filed July 11, 2024—not a T3 Defense Inc. filing or a standalone 2023 Q4 report. The financial statements primarily reflect Old Nukkleus; its business combination with Brilliant Acquisition Corporation closed December 22, 2023 and was accounted for as a reverse recapitalization. The combined company traded as NUKK and NUKKW.
Business context and financial results
Nukkleus provides foreign-exchange trading technology and financial services, including cross-border payment processing through Digital RFQ. FY2023 results were dominated by a related-party general-services agreement (GSA) with TCM; the company says it is shifting its focus toward digital-asset-related services.
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $21.30 million | $21.51 million |
| Gross profit (loss) | $(0.34) million | $(0.66) million |
| Operating loss | $(17.46) million | $(11.14) million |
| Net loss | $(17.43) million; $(1.73) per share | $(11.85) million; $(1.21) per share |
| Operating cash flow | $(1.23) million | $1.62 million |
GSA revenue was $19.2 million in both years, with gross profit of $425,000 in FY2023 versus $300,000 in FY2022 (2.2% versus 1.6% gross margin). Financial-services revenue fell 9.3% to $2.10 million; the segment recorded a $768,000 gross loss, improving from a $961,000 loss, with gross margin improving to negative 36.6% from negative 41.6%. Management attributed the revenue decline partly to GBP depreciation and disruption to U.S. banking rails. Financial-services trading volume rose 23.3% to $432.1 million; active clients increased to 217 from 93.
Liquidity, debt, and material changes
At September 30, 2023, cash available to the company was $19,318, excluding $672,501 of customer custodial cash. Current assets were $2.93 million and current liabilities $9.12 million, producing a $6.20 million working-capital deficit, up from $3.79 million a year earlier. Total liabilities were $9.55 million, versus total assets of $3.35 million; stockholders’ equity was a $6.19 million deficit. Current liabilities included $6.81 million due to affiliates; non-current related-party loans were $421,000.
Cash declined by $1.69 million during FY2023. Investing activities used $1.11 million, primarily for related-party notes receivable, and financing provided $418,000 from related-party loans. The company recorded $11.91 million of impairment losses—$5.70 million on intangible assets and $6.21 million on its Jacobi investment—and $1.18 million of bad-debt expense. The impairments were tied to reduced expected recoverability; management said Match-related projections had not been achieved. Net loss increased 47.1% year over year.
Outlook, risks, and unusual items
- Going concern: The auditor highlighted recurring losses and a net capital deficiency that raise substantial doubt about the company’s ability to continue as a going concern. Management cited financing needs and expense management, while also stating it believed resources could cover the 12 months after issuance; it noted TCM had committed to inject capital if other funding was delayed.
- GSA termination and concentration: TCM accounted for 90.2% of FY2023 revenue. The company reported that, due to TCM’s non-payment, it advised TCM that the GSA had been terminated. The filing says GSA services historically generated substantially most revenue, making replacement revenue a key uncertainty.
- Related parties and collectability: The GSA customer and major service providers are related parties. A related-party customer represented 95.2% of receivables and amounts due from affiliates at year-end. The company also recorded allowances against related-party lending and disclosed write-offs; verify balances and subsequent collections.
- Financing and dilution: Subsequent to year-end, related-party debt of $2.73 million and $270,000 was converted into shares. In June 2024, the company disclosed a $312,500 principal note for $250,000 cash proceeds, bearing 12% interest, with a $0.25 conversion price and a warrant for 1.2 million shares. The lender could provide an additional $500,000, subject to terms including restrictions on other financing during the investment period. The White Lion equity purchase agreement was terminated in February 2024.
- Controls and other risks: Management concluded disclosure controls and internal control over financial reporting were ineffective at September 30, 2023, citing a material weakness involving complex, non-routine transactions and entity-level controls. Remediation was underway. Key additional risks include limited liquidity, customer and banking-partner concentration, regulatory uncertainty, cybersecurity, and reliance on third parties. The filing reports no material legal proceedings.
- Outlook: No formal quantitative guidance is provided. Management expected efforts to expand financial services to support revenue growth, but described near-term segment margins as likely to remain near current levels with only minimal improvement.
Most important facts for investors to verify
- Confirm the issuer: the supplied filing is for Nukkleus Inc., not T3 Defense Inc.; confirm the intended company and reporting period.
- Check the status and enforceability of the TCM GSA termination, amounts owed by TCM, and the company’s plan to replace the concentrated revenue stream.
- Reconcile liquidity disclosures, including unrestricted cash versus customer funds, affiliate balances, debt maturities, and the stated going-concern funding plans.
- Review the terms, share dilution, and financing restrictions from subsequent loans, debt conversions, and warrants, and confirm the additional financing actually received.
- Assess impairment assumptions, related-party receivable allowances and write-offs, and progress remediating the material weakness in financial reporting controls.